This medication treats an issue that affects patients of all ages, some associated with Covid infection. Here's why ...
Citi has initiated coverage of EyePoint (EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wAMD market. Read more here.